Vanguard Group Inc. Sells 140,238 Shares of Prestige Consumer Healthcare Inc. $PBH

Vanguard Group Inc. cut its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 2.5% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,492,748 shares of the company’s stock after selling 140,238 shares during the quarter. Vanguard Group Inc. owned about 0.11% of Prestige Consumer Healthcare worth $342,747,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently modified their holdings of PBH. Texas Yale Capital Corp. lifted its position in Prestige Consumer Healthcare by 15.8% during the 3rd quarter. Texas Yale Capital Corp. now owns 8,430 shares of the company’s stock valued at $526,000 after acquiring an additional 1,150 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Prestige Consumer Healthcare by 30.1% during the third quarter. JPMorgan Chase & Co. now owns 459,228 shares of the company’s stock valued at $28,656,000 after purchasing an additional 106,224 shares in the last quarter. State of New Jersey Common Pension Fund D lifted its holdings in shares of Prestige Consumer Healthcare by 46.7% during the third quarter. State of New Jersey Common Pension Fund D now owns 32,499 shares of the company’s stock valued at $2,028,000 after purchasing an additional 10,343 shares during the last quarter. PNC Financial Services Group Inc. boosted its position in shares of Prestige Consumer Healthcare by 8.9% in the 3rd quarter. PNC Financial Services Group Inc. now owns 5,617 shares of the company’s stock worth $350,000 after purchasing an additional 457 shares in the last quarter. Finally, Public Sector Pension Investment Board grew its stake in shares of Prestige Consumer Healthcare by 1.5% in the 3rd quarter. Public Sector Pension Investment Board now owns 191,924 shares of the company’s stock worth $11,976,000 after buying an additional 2,790 shares during the last quarter. Institutional investors own 99.95% of the company’s stock.

Key Prestige Consumer Healthcare News

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Positive Sentiment: Bleakley Financial Group reported a new purchase of 10,912 PBH shares (~$681,000), signaling fresh institutional buying interest in the stock. Bleakley Investment
• Positive Sentiment: Zacks bumped a few quarterly estimates: Q4 2026 was raised to $1.59 (from $1.54), Q3 2027 to $1.21 (from $1.20) and Q4 2027 to $1.32 (from $1.26) — small upside revisions that suggest pockets of strength in certain quarters.
• Neutral Sentiment: Zacks Research continues to carry a “Hold” rating on PBH even as it updates estimates; the firm’s commentary so far is a recalibration of numbers rather than a rating change. Consensus full‑year EPS referenced by Zacks remains near $4.50 for the current year.
• Negative Sentiment: Zacks pared several near‑term and fiscal forecasts, which is the main driver of downward pressure: Q1 2027 EPS cut to $1.09 (from $1.24), Q1 2028 to $1.14 (from $1.26), Q2 2028 to $1.30 (from $1.33), Q3 2028 to $1.26 (from $1.28), FY2027 to $4.77 (from $4.84) and FY2028 to $5.06 (from $5.19). Those trims signal slower expected earnings growth and likely explain why the stock is underperforming today.

Prestige Consumer Healthcare Stock Down 1.3%

Prestige Consumer Healthcare stock opened at $69.30 on Friday. The stock has a fifty day moving average of $65.26 and a 200 day moving average of $63.48. The stock has a market cap of $3.28 billion, a PE ratio of 18.33, a price-to-earnings-growth ratio of 2.21 and a beta of 0.43. Prestige Consumer Healthcare Inc. has a one year low of $57.25 and a one year high of $90.04. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.93 and a current ratio of 3.11.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Thursday, February 5th. The company reported $1.14 earnings per share for the quarter, missing the consensus estimate of $1.16 by ($0.02). The business had revenue of $283.44 million during the quarter, compared to the consensus estimate of $286.93 million. Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.Prestige Consumer Healthcare’s revenue for the quarter was down 2.4% on a year-over-year basis. During the same quarter last year, the company earned $1.22 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. As a group, sell-side analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on PBH. Jefferies Financial Group lowered their price objective on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a research note on Friday, January 30th. Canaccord Genuity Group decreased their target price on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating for the company in a report on Friday, November 7th. Zacks Research upgraded shares of Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research note on Monday, November 10th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a report on Thursday, January 22nd. Three analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, Prestige Consumer Healthcare currently has an average rating of “Hold” and a consensus target price of $80.60.

Insider Activity at Prestige Consumer Healthcare

In other news, VP Jeffrey Zerillo sold 1,000 shares of Prestige Consumer Healthcare stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $65.93, for a total transaction of $65,930.00. Following the transaction, the vice president directly owned 41,048 shares of the company’s stock, valued at $2,706,294.64. The trade was a 2.38% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.40% of the stock is owned by company insiders.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).